## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%); PEG 1.51 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.03)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Hologic, Inc. (NASDAQ:HOLX) Receives Average Recommendation of "Hold" from Brokerages**
- Source: MarketBeat | 20251208T031435 | Neutral | Relevance: 98%
-  Hologic, Inc. (NASDAQ:HOLX) has received an average "Hold" recommendation from twenty brokerages, with an average 12-month price target of $79.67. Recent insider selling notable from CEO Stephen Macmillan and a director, reducing their stakes significantly. The company recently beat Q3 earnings estimates, with EPS of $1.13 and revenue of $1.05 billion, and maintains a market capitalization of approximately $16.7 billion.

**2. 2Xideas AG Decreases Position in Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251209T081924 | Neutral | Relevance: 98%
- 2Xideas AG significantly reduced its stake in Hologic, Inc. by 45.2% in the second quarter, selling over 57,000 shares. Despite this, other institutional investors like Invesco Ltd. and Nordea Investment Management AB increased their holdings in the medical equipment provider. Hologic's stock opened at $74.85, has a market cap of $16.68 billion, and has a consensus "Hold" rating from analysts with an average price target of $79.67.

**3. L2 Asset Management LLC Sells 36,643 Shares of Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251208T122917 | Neutral | Relevance: 98%
- L2 Asset Management LLC significantly reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 58.9% in the second quarter, selling 36,643 shares and now holding 25,551 shares valued at $1.67 million. Despite insider selling from CEO Stephen Macmillan and other directors, institutional ownership remains high at 94.73%. Hologic recently surpassed earnings and revenue expectations, reporting $1.13 EPS and $1.05 billion in revenue, leading to a consensus "Hold" rating from analysts with an average target price of $79.67.

**4. HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026?**
- Source: Finviz | 20251208T155505 | Somewhat-Bullish | Relevance: 98%
-  Hologic (HOLX) shares have seen a 16.1% increase over the last six months, outperforming its industry and competitors, driven by clinical data strength, molecular diagnostics, and breast health innovations. The company is currently undergoing a take-private process by Blackstone and TPG at $76 per share plus a potential CVR. Despite trading close to the offer price and facing some external challenges, Hologic's strong divisional performance, new clinical evidence, and attractive valuation suggest existing holders may consider retaining the Zacks Rank #3 (Hold) stock.

**5. Mammography Machine Market to hit US$ 4.1 billion by 2033, North**
- Source: openPR.com | 20251209T060914 | Bullish | Relevance: 97%
- The global Mammography Machine Market is projected to reach US$ 4.1 billion by 2033, growing from US$ 2.6 billion in 2024 at a CAGR of 5.1%. This growth is fueled by increasing breast cancer cases, technological advancements, and government health initiatives, with North America currently dominating the market share. Key industry developments include new FDA clearances and product launches from major players like GE HealthCare, Siemens Healthineers AG, and Hologic, Inc., emphasizing digital, 3D tomosynthesis, and AI integration.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $76 | $69 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($0.27M) |
| Sells | 25 ($6.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.51 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.5x). Analyst sentiment positive (1 raises, avg +10%). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.7B |
| Beta | 0.70 |
| 52W Range | $51.90 - $77.32 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.51 |
| Forward P/E | 15.0 |
| Current P/E | 16.4 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.90% (CS: 40) | Neutral |
| RSI_14 | 64.3 | Neutral |
| MACD Histogram | -0.15 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.031x | Above |
| vs SMA200 | 1.144x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.83
- **Stop Loss:** $74.03 (1.1% risk)
- **Target:** $75.63 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 625
- **Position Value:** $46,768.75
- **Portfolio %:** 46.77%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*